----

----

|  VENTIV COMMERCIAL SERVICES,      LLC |   |   |   |   |
|--------------------------------------------|--------|--------|--------|--------|
| By:       /s/ TERRELL G. HERRING      |   |   |   |   |
| Terrell      G. Herring                    |   |   |   |   |
| President      and Chief Executive Officer |   |   |   |   |

|                            |   |   |   |   |
|---------------------------------|--------|--------|--------|--------|
|  OMP, INC.                 |   |   |   |   |
| By:       /s/ PRESTON ROMM |   |   |   |   |
| Preston      Romm               |   |   |   |   |
| CFO                             |   |   |   |   |

----

| ·   | VAS      shall complete a maximum of 10 telephone interviews with targeted MCO and      PBM stakeholders who are geographically dispersed within the United      States.  A minimum of 5 interviews will be      conducted. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | VAS      shall complete a maximum of 7 telephone interviews with targeted retail      pharmacies that are geographically dispersed within the United      States.  A minimum of 3 interviews will be      conducted. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | The      survey instrument will be designed by VAG with clinical and product input      supplied by Obagi and final approval also by  Obagi. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Each      interview will be no longer than 45minutes. |
|--------------------|-------------------------------------------------------|

| ·   | The      interviews will examine the current situation and challenges facing their      new product, SoluCLENZ Rx GelTM, any restrictions placed on the brand      within the payors, level and tier placement, and product categorization      within the pharmacy systems.  Secondarily, the interviews will      examine the formulary placement of the two main competitors in this      category, BenzaClin Gel and DuacGel. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Deliverable      would be in the form of a MS PowerPoint report with associated      recommendations from inVentiv onsolutions. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------|

| ·   | VAS      will work closely with Obagi to develop a list of questions the sales      force can utilize in the field when dealing with reimbursement      objections.  This resource will assist the sales force with      obtaining information from the physician or office staff regarding      reimbursement issues with SoluCLENZ Gel and better allow the district      manager to provide support. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | VAS      will work closely with Obagi to develop processes and procedures the field      sales force will follow when submitting these objections to their District      Managers. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | General      support will be in the form of responses and advice within 24 hours of the      incoming request; |
|--------------------|----------------------------------------------------------------------------------------------------------------|

| ·   | VAG      will develop a prioritized target account list, including where necessary      contracted PBMs (final list to be approved by Obagi), with an associated      time line for engagement; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | VAS      will deploy no more than one National Account Manager (NAM) unless      otherwise approved by Obagi, to provide ongoing support in the following      area’s; MCO, Trade and Pharmacy account management, support and training,      field sales force support and strategic and tactical    planning. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Support      would be on a billable hour basis of [ 4* ] per hour per VAG headquarters      personnel, regardless of title or level, and supported by monthly time and      event logs; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Fifty      percent (50%) time allocation: [ 5* ] per month per  NAM; |
|--------------------|----------------------------------------------------------------------|

| ·   | Full      Time allocation: [ 6* ] per month perNAM. |
|--------------------|-----------------------------------------------------|

| C.   | NDC      PAYOR AUDIT |
|----------------|----------------------|

| ·   | VAG will have the NDC numbers for      SoluClenzTM, 62032-0121-10, Duac®  (0145-2371-05 and      0145-2367-01)and BenzaClin® (0066-0494-50) input into a      real-time Rx30 claims adjudication system for UnitedHealth Group, Aetna and Cigna.  The      results will be a report that communicates the edits and prompts sent form      these payors to retail pharmacies submitting any of the three products for      reimbursement. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | October      20 – Obagi approves initial project scope and  terms |
|--------------------|-------------------------------------------------------------------------|

| ·   | October      20 – October 23 – Discussion with Obagi team, develop discussion guide and      start recruiting. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------|

| ·   | October      23 – 31 – NDC Audit conducted andreported |
|--------------------|--------------------------------------------------------------------|

| ·   | October      27 – October 31 – Interviews conducted; Target account list and timeline      developed |
|--------------------|------------------------------------------------------------------------------------------------------------------|

| ·   | November      3  –  November 7 – Research results are analyzed and      report is prepared and submitted. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | NAM      deployment can be initiated after November 3,  2008 |
|--------------------|--------------------------------------------------------------|

| F.   | Expansion |
|----------------|-----------|

----

| o   | BA/BS      Degree |
|---------------|-------------------|

| o   | Pharmaceuticals,      Health Care Products, Durable Medical Equipment or Medical Technology      sales and account management experience: 5-10  years |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

| o   | Documented      successful sales or sales management track  record |
|---------------|--------------------------------------------------------------------|

| o   | Demonstrated      verbal and written communication and negotiation  skills |
|---------------|----------------------------------------------------------------------------|

| o   | Demonstrated      platform and presentation skills |
|---------------|----------------------------------------------------|

| o   | MBA      or equivalent experience |
|---------------|-----------------------------------|

| o   | Personnel      management experience |
|---------------|--------------------------------------|

| o   | Scientific,      clinical, pharmacy or medical degree /  experience |
|---------------|---------------------------------------------------------------------|

| o   | Brand      management in health care industrysector |
|---------------|-----------------------------------------------------|

| o   | Direct      management supervision of pharmaceutical sales  personnel |
|---------------|-----------------------------------------------------------------------|

| o   | Regional      or national managed markets accountmanagement |
|---------------|-------------------------------------------------------------|

| o   | Institutional,      Health System, MCO, GPO and Specialtyexperience |
|---------------|---------------------------------------------------------------------|

| o   | Professional      external corporate sales or account management  experience |
|---------------|------------------------------------------------------------------------------|

| o   | Business      to Business negotiation and sellingexperience |
|---------------|-------------------------------------------------------------|

| o   | Excellent      demonstrated communications skills: verbal and  written |
|---------------|------------------------------------------------------------------------|

| o   | Excellent      analytical and problem solvingskills |
|---------------|-----------------------------------------------------|

----